Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 11 at 9:00 PM CDT and Saturday, Apr 12 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

Merck
CN
HomeWebinarsBalancing Risk in Biopharma

Balancing Risk in Biopharma



WEBINAR

Biotech organizations can encounter a variety of challenges, both expected and unexpected, during biopharmaceutical development. Anticipating and mitigating these challenges will ensure that the process development and manufacturing timelines and deliverables will be maintained. In this webinar industry experts will provide insights on how biotech organizations and their CDMO partners can effectively plan and execute a successful drug development program, from pre-clinical to IND. Two case studies will be presented that illustrate how analytical and process development activities are performed to meet timelines and process needs.

In this webinar, you will learn:

  • Strategies used and activities performed to achieve high-concentration formulation to address client’s testing needs.
  • Analytical and process development strategies that reduce the time required to produce biologics, while balancing risk and cost.

Speakers

Abigail Guce-Merriam, Ph.D.

Abigail Guce-Merriam, Ph.D.

Merck

Manager, Downstream Process Development

Abigail Guce-Merriam leads the downstream process development, located in our Burlington, MA, facility. Her group mainly focuses on client molecule downstream process development, process tech transfers to GMP production, and DS formulation study.

A biophysicist and structural biologist by training, she holds a Ph.D. from the University of Massachusetts-Amherst. Prior to joining the company in 2018, Abby was a downstream process development SME and protein purification expert in MassBiologics (CDMO) and UMASS Medical School Structural Lab.

Joshua Arias

Joshua Arias

Merck

Technical Lead, CDMO Services

As a technical lead in our company, Josh has served as a technical point of contact ensuring technical activities are completed on track. Josh has more than 25 years of experience in applied separations in the non-GMP pilot and GMP manufacturing environments, including managing clinic manufacturing operations in both upstream and downstream areas. His expertise includes technology transfer, process implementation, process monitoring, and troubleshooting investigations.  

Josh is a chemical engineer and has a B.S from Worcester Polytechnic Institute and a M.E. degree from Tufts University.

Webinar Information

Pharma and biopharma manufacturing

  • mRNA

  • Duration:1h

  • Language:English

  • Session 1:presented June 16, 2022

    Watch Now

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?